The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
Open accessAbstract
Background: Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years. Content: Recent data demonstrate that apolipoprotein B (apo B) is a better measure of circulating LDL particle number (LDL-P) concentration and is a more reliable indicator of risk than LDL-C, and there is growing support for the idea that addition of apo B measurement to the routine lipid panel for assessing and monitoring patients at risk for cardiovascular disease (CVD) would enhance patient management. In this report, we review the studies of apo B and LDL-P reported to date, discuss potential advantages of their measurement over that of LDL-C, and present information related to standardization. Conclusions: In line with recently adopted Canadian guidelines, the addition of apo B represents a logical next step to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) and other guidelines in the US. Considering that it has taken years to educate physicians and patients regarding the use of LDL-C, changing perceptions and practices will not be easy. Thus, it appears prudent to consider using apo B along with LDL-C to assess LDL-related risk for an interim period until the superiority of apo B is generally recognized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoB can be measured in the nonfasting state because even at peak postprandial concentrations, the number of chylomicron-apoB48 particles in healthy individuals is usually < 1% and the number of VLDL-apoB100 particles is < 10% of the number of LDL-apoB100 particles [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is the structural protein for all non-HDL lipoproteins and exists as 2 isoforms: apoB100, the major isoform in VLDL, IDL, LDL, and Lp(a), and apoB48 in chylomicrons and chylomicron remnants [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Taken together with the evidence that apoB can be measured more accurately, more precisely, and more selectively than LDL-C or non-HDL-C,1,29–31”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Measurement of apolipoprotein B (apoB), the major protein component of LDL, or advanced measurement of LDLP (not yet widely available) can also be used to assess the number of LDL particles [10,12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“ApoB can be measured in the nonfasting state because even at peak postprandial concentrations, the number of chylomicron-apoB48 particles in healthy individuals is usually < 1% and the number of VLDL-apoB100 particles is < 10% of the number of LDL-apoB100 particles [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Since each atherogenic particle contains one molecule of apoB, concentrations of apoB are therefore considered to be a direct measure of the total number of lipoproteins causing cardiovascular disease, that is, LDL, remnants, and Lp(a) [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Cholesterol in the Prediction of Atherosclerotic Disease
Kannel, W. B., Castelli, W. P., & Gordon, T. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-1-85 · Cited by 1,314
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Sharrett, A. R., Ballantyne, C. M., Coady, S., HEISS, G. M., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 942
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744
Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy
Jeyarajah, E. J., Cromwell, W. C., & Otvos, J. D. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.006 · Cited by 734
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 716
Flagged first, then by citations
Research works printed but not linked: 4
- 2003, JAMC, 169, 921
- 2002, Textbook of cardiovascular medicine, 2nd ed, 2
- 2007, Circulation, 116, 3481
- 2001, Clin Chem Lab Med, 39, 426
Cited by
Sorted by citations
Items 101–200 of 325
Vitamin D insufficiency in obese children and relation with lipid profile
Rusconi, R. E., Cosmi, V. D., Ghilardi, G., Giavoli, C., & Agostoni, C. V. (2015) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2014.959902 · Cited by 39
Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC‐MS/MS
Ceglarek, U., Dittrich, J., Becker, S., Baumann, F., Kortz, L., & Thiery, J. (2013) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300034 · Cited by 38
The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk
Walldius, G. (2012) · InTech eBooks · doi:10.5772/47869 · Cited by 36
Heravifard, S., Neyestani, T. R., Nikooyeh, B., Majd, H. A., Houshiarrad, A., Kalayi, A., Shariátzadeh, N., Zahedirad, M., Tayebinejad, N., Salekzamani, S., et al. (2013) · Journal of the American College of Nutrition · doi:10.1080/07315724.2013.767659 · Cited by 36
Michel, C. C., Nanjee, M. N., Olszewski, W. L., & Miller, N. E. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m055053 · Cited by 36
Toth, P. P., Jones, S. R., Monsalvo, M. L., Elliott‐Davey, M., López, J. A. G., & Banach, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014129 · Cited by 36
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Santos, R. D., Raal, F. J., Donovan, J. M., & Cromwell, W. C. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.12.008 · Cited by 37
Grundy, S. M., Vega, G. L., Tomassini, J. E., & Tershakovec, A. M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.003 · Cited by 33
Nutritional management of hyperapoB
Lamantia, V., Sniderman, A. D., & Faraj, M. (2016) · Nutrition Research Reviews · doi:10.1017/s0954422416000147 · Cited by 35
Chi, X., Zhang, T., Zhang, D., Yu, W., Wang, Q., & Zhen, J.-L. (2016) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.15-147 · Cited by 32
Cao, J., Steffen, B. T., Guan, W., Remaley, A. T., McConnell, J. P., Palamalai, V., & Tsai, M. Y. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.12.013 · Cited by 31
Self-citationAli, Z., Ma, H., Wali, A., Ayim, I., & Sharif, M. N. (2019) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2019.100265 · Cited by 31
Clouet-Foraison, N., Gaie-Levrel, F., Gillery, P., & Delatour, V. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0091 · Cited by 30
Skulas-Ray, A. C., Alaupovic, P., Kris-Etherton, P. M., & West, S. G. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.12.001 · Cited by 30
Sondermeijer, B. M., Rana, J. S., Arsenault, B. J., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12129 · Cited by 30
Guadagno, P. A., Bellin, E. G. S., Harris, W. S., Dayspring, T. D., Hoefner, D. M., Thiselton, D. L., Stanovick, B., Warnick, G. R., & McConnell, J. P. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.013 · Cited by 29
Self-citationVerbeek, R., Boyer, M., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J. P., Wareham, N. J., Khaw, K., & Arsenault, B. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307995 · Cited by 30
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 43
Llauradó, G., Amigó, N., Cano, A., Ballesta, S., Albert, L., Mazarico, I., Fernández‐Veledo, S., Pedro‐Botet, J., Vendrell, J. J., & González-Clemente, J. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111875 · Cited by 28
Verbree-Willemsen, L., Zhang, Y., Gijsberts, C. M., Schoneveld, A. H., Wang, J., Lam, C. S. P., Vernooij, F., Bots, M. L., Peelen, L. M., Grobbee, D. E., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.05.098 · Cited by 28
Clouet-Foraison, N., Marcovina, S. M., Guerra, E., Aarsand, A. K., Coşkun, A., Díaz–Garzón, J., Fernández–Calle, P., Sandberg, S., Ceriotti, F., & Carobene, A. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa054 · Cited by 27
Mathews, S. C., Mallidi, J. R., Kulkarni, K. R., Toth, P. P., & Jones, S. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033692 · Cited by 27
Bañuls, C., Bellod, L., Jover, A., Martínez-Triguero, M. L., Víctor, V. M., Rocha, M., & Hernández‐Mijares, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.09.047 · Cited by 26
Cho, D.-S., Woo, S., Kim, S., Byrne, C. D., Kong, J.-H., & Sung, K. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-55 · Cited by 26
Vandermeersch, A., Ameye, S., Puype, D., Petitjean, D., Buyzere, M. D., & Langlois, M. R. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.05.038 · Cited by 26
Targets for LDL-lowering therapy
Sniderman, A. D. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832ca1d6 · Cited by 26
Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis
Bjørnevik, K., O’Reilly, É. J., Cortese, M., Furtado, J. D., Kolonel, L. N., Marchand, L. L., McCullough, M. L., Paganoni, S., Schwarzschild, M. A., Shadyab, A. H., et al. (2020) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2020.1822411 · Cited by 25
Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change?
Cole, J., Zubirán, R., Wolska, A. T., Jialal, I., & Remaley, A. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175737 · Cited by 23
ApoB versus non-HDL-cholesterol: Diagnosis and cardiovascular risk management
de Nijs, T., Sniderman, A. D., & Graaf, J. D. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.847897 · Cited by 25
Xiao, S., Liu, R., Wei, Y., Lin, F. W., Lv, X., & Tang, F. (2016) · Environmental Pollution · doi:10.1016/j.envpol.2016.05.007 · Cited by 25
Varvel, S. A., Dayspring, T. D., Edmonds, Y., Thiselton, D. L., Ghaedi, L., Vörös, S., McConnell, J. P., Sasinowski, M., Dall, T., & Warnick, G. R. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.11.005 · Cited by 24
Self-citationDayspring, T. D. (2011) · International Journal of Women s Health · doi:10.2147/ijwh.s16702 · Cited by 25
Zhang, C., Ni, J., & Chen, Z. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.06.010 · Cited by 23
Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease
Ohwada, T., Sakamoto, T., Kanno, Y., Yokokawa, S., Amami, K., Nakazato, K., Takeishi, Y., & Watanabe, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212539 · Cited by 22
Apolipoprotein B: the Rosetta Stone of lipidology
Glavinovic, T., & Sniderman, A. D. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000596 · Cited by 22
Use of Emerging Lipoprotein Risk Factors in Assessment of Cardiovascular Risk
Grundy, S. M. (2012) · JAMA · doi:10.1001/jama.2012.6896 · Cited by 22
Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review
Bagherniya, M., Johnston, T. P., & Sahebkar, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200427092114 · Cited by 22
Parent-of-Origin Effects of the APOB Gene on Adiposity in Young Adults
Hochner, H., Allard, C., Granot‐Hershkovitz, E., Chen, J., Sitlani, C. M., Sazdovska, S., Lumley, T., McKnight, B., Rice, K. M., Enquobahrie, D. A., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005573 · Cited by 23
Virani, S. S., Pompeii, L. A., Lincoln, A. E., Dunn, R. E., TUCKER, A. M., Nambi, V., Nasir, K., Vogel, R. A., Boone, J. L., Roberts, A. J., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.03.031 · Cited by 21
Schizophrenia Treatment Guidelinesin the United States
Moore, T. A. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.1.6 · Cited by 20
Lipoprotein Particle Concentrations in Children and Adults following Kawasaki Disease
Lin, J., Jain, S., Sun, X., Liu, V., Sato, Y. Z., Jimenez-Fernandez, S., Newfield, R. S., Pourfarzib, R., Tremoulet, A. H., Gordon, J. B., et al. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.06.017 · Cited by 20
Baruch, L., Agarwal, S., Gupta, B. P., Haynos, A. F., Johnson, S., Kelly-Johnson, K., & Eng, C. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.05.003 · Cited by 20
Identifying pseudohypertriglyceridemia in clinical practice
Backes, J. M., Dayspring, T. D., Hoefner, D. M., Contois, J. H., McConnell, J. P., & Moriarty, P. M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.52 · Cited by 20
Self-citationSoran, H., France, M. W., Kwok, S., Dissanayake, S., Charlton-Menys, V., Younis, N. N., & Durrington, P. N. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.010277 · Cited by 20
Cardiovascular Disease Risk in Patients with Rheumatic Diseases
Mackey, R. H., Kuller, L. H., & Moreland, L. W. (2016) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.008 · Cited by 20
Bowden, R. G., Wilson, R. L., & Beaujean, A. A. (2011) · Journal of Nephrology · doi:10.5301/jn.2011.6376 · Cited by 20
Langlois, M. R., & Nordestgaard, B. G. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1036-1 · Cited by 19
Impact of triglycerides on lipid and lipoprotein biology in women
Dayspring, T. D., & Pokrywka, G. S. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.05.002 · Cited by 19
A Comprehensive Review of the Prevention and Treatment of Heart Disease with a Plant-Based Diet
Rose, S. D. (2018) · Journal of Cardiology & Cardiovascular Therapy · doi:10.19080/jocct.2018.12.555847 · Cited by 19
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study
Folse, H. J., Goswami, D., Rengarajan, B., Budoff, M. J., & Kahn, R. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.027 · Cited by 19
Dhar, I., Lysne, V., Seifert, R., Svingen, G. F. T., Ueland, P. M., & Nygard, O. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.038 · Cited by 19
Sundvall, J., Leiviskä, J., Laatikainen, T. K., Peltonen, M., Salomaa, V. V., Vanhala, M. J., Korpi-Hyövälti, E., Lauronen, J., & Alfthan, G. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-63 · Cited by 20
Wilson, D. P., Friedman, M., Marulkar, S., Hamby, T., & Bruckert, É. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.020 · Cited by 18
Genetic Markers for Coronary Artery Disease
Veljković, N., Zarić, B. L., Đorić, I., Obradovic, M. M., Sudar-Milovanovic, E. M., Radak, D. J., & Isenović, E. R. (2018) · Medicina · doi:10.3390/medicina54030036 · Cited by 18
Vine, D. F., Beilin, L. J., Burrows, S., Huang, R.-C., Hickey, M., Hart, R., Proctor, S. D., & Mori, T. A. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa061 · Cited by 17
Low-density lipoprotein-lowering strategies
Sniderman, A. D., Graaf, J. D., & Couture, P. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353fed5 · Cited by 17
Pluralism of viewpoints as the antidote to intellectual conflict of interest in guidelines
Sniderman, A. D., & Furberg, C. D. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.009 · Cited by 17
Reiner, Ž. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711418946 · Cited by 17
Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study
Harborg, S., Ahern, T. P., Feldt, M., Rosendahl, A. H., Cronin-Fenton, D. P., Melander, O., & Borgquist, S. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06462-7 · Cited by 16
Takagi, H., & Umemoto, T. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.043 · Cited by 17
Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?
Meeusen, J. W., Donato, L. J., & Jaffe, A. S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000313 · Cited by 17
Du, R., Wu, X., Peng, K., Lin, L., Li, M., Xu, Y. H., Xu, M., Chen, Y., Li, D., Lu, J., et al. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12904 · Cited by 16
Solomon, D. H., Demler, O., Rist, P. M., Santacroce, L. M., Tawakol, A. A., Giles, J. T., Liao, K. P., & Bathon, J. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032095 · Cited by 15
Huang, Y.-T., Ho, L., Hsu, H., Tu, Y., & Chien, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.832614 · Cited by 15
Ramanjaneya, M., Butler, A. E., Bashir, M., Bettahi, I., Moin, A. S. M., Ahmed, L., Elrayess, M. A., Hunt, S. C., Atkin, S. L., & Abou‐Samra, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001925 · Cited by 16
Emerging roles of sortilin in affecting the metabolism of glucose and lipid profiles
Su, X., Chen, X., Wang, B., Chen, L., & Dai, C. (2021) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.6601 · Cited by 15
Mangalmurti, S. S., & Davidson, M. H. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0190-3 · Cited by 13
Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia
Guan, Y., Hou, X., Tian, P., Ren, L., Tang, Y., Song, A., Zhao, J., Gao, L., & Song, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.646185 · Cited by 14
Leiviskä, J., Sundvall, J., Alfthan, G., Jauhiainen, M., & Salomaa, V. V. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.03.015 · Cited by 14
Physical Activity, Blood Lipids, and Lipoproteins
Mestek, M. L. (2009) · American Journal of Lifestyle Medicine · doi:10.1177/1559827609334885 · Cited by 14
Lipid profile abnormalities associated with endocrine disorders
Szczepanek‐Parulska, E., Sokołowski, J., Dmowska, D., Klimek, J., Stasikowski, T., Zdebski, P., Olejarz, M., Gac, A., Bartecki, M., & Ruchała, M. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0059 · Cited by 14
de Diabetes, G. D. T. D. M. Y. E. C. D. L. S. E. (2010) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.03.001 · Cited by 14
Simone, R. D. (1994) · Springer eBooks · doi:10.1007/978-3-642-78956-4_5 · Cited by 14
Rizzo, J. A., Mallow, P. J., Waters, H. C., & Pokrywka, G. S. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.06.004 · Cited by 13
Identification of a threshold to discriminate fasting hypertriglyceridemia with postprandial values
Sevilla-González, M. D. R., Aguilar-Salinas, C. A., Muñóz-Hernández, L. L., Almeda‐Valdés, P., Mehta, R., Zubirán, R., Bello‐Chavolla, O. Y., Gómez‐Velasco, D., Vargas‐Vázquez, A., Viveros-Ruiz, T. L., et al. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0803-8 · Cited by 13
Mendez, R. L., Miranda, C. L., Armour, C. R., Sharpton, T. J., Stevens, J. F., & Kwon, J. Y. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa072 · Cited by 14
Eick, G. N., Kowal, P. R., Barrett, T. M., Thiele, E. A., & Snodgrass, J. J. (2017) · Biodemography and Social Biology · doi:10.1080/19485565.2017.1283582 · Cited by 13
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H. H. E., Borén, J., Bruckert, É., Catapano, A. L., Cobbaert, C. M., et al. (2021) · Laboratory Service · doi:10.17116/labs20211001145 · Cited by 13
Comparison of cardiovascular disease risk associated with 3 lipid measures in Japanese adults
Takeuchi, T., Nemoto, K.-I., Takahashi, O., Urayama, K. Y., Deshpande, G. A., & Izumo, H. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.06.005 · Cited by 12
Toth, P. P., Insull, W., Padley, R. J., Parreño, R. A. N., Jiang, P. X., Thakkar, Krause, S. L., & Superko, H. R. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s14053 · Cited by 12
Wölter, M., Okai, C. A., SMITH, D. S. H., Ruß, M., Rath, W. H., Pecks, U., Borchers, C. H., & Glocker, M. O. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800017 · Cited by 12
Refining Lipoprotein Assessment in Diabetes: Apolipoprotein B Makes Sense
Ganda, O. P. (2009) · Endocrine Practice · doi:10.4158/ep09064.rar · Cited by 12
Management of Lipids in Patients with Diabetes
Mbue, N. D., Mbue, J. E., & ANDERSON, J. A. (2017) · Nursing Clinics of North America · doi:10.1016/j.cnur.2017.07.009 · Cited by 12
Sniderman, A. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.010 · Cited by 12
Jenkins, M. G., & Goldsmith, D. J. A. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353b988 · Cited by 11
Wang, W., Khan, S. H., Blackett, P. R., Alaupovic, P., & Lee, E. T. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.06.007 · Cited by 11
Briers, P.-J., & Langlois, M. R. (2022) · University of Zagreb University Computing Centre (SRCE) · Cited by 11
Prevalence of cardiovascular disease risk factors in Tallinn, Estonia
Kaldmäe, M., Zemtsovskaja, G., Abina, J., Land, T., & Viigimaa, M. (2017) · Medicina · doi:10.1016/j.medici.2017.07.002 · Cited by 11
Nishikido, T., & Ray, K. K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14851 · Cited by 11
Ihm, S., Chung, W., Lee, J.-M., Hwang, B., Yoo, K., Her, S., Song, W.-H., Chae, I., Park, T., Kim, J. H., et al. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.08.002 · Cited by 11
Zhang, B., Kawachi, E., Matsunaga, A., Imaizumi, S., Noda, K., Uehara, Y., Miura, S.-I., Yoshinaga, K., Kuroki, M., & Saku, K. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0381 · Cited by 10
Approach to risk stratification of atherosclerotic cardiovascular disease
Esau, D., & Abramson, B. L. (2022) · Canadian Family Physician · doi:10.46747/cfp.6809654 · Cited by 11
Martínez‐Hervás, S., Real, J. T., Priego, M. A., Carratalá, A., Sniderman, A. D., Carmena, R., & Ascaso, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02998.x · Cited by 10
Grabner, M., Winegar, D. A., Punekar, R. S., Quimbo, R. A., Cziraky, M. J., & Cromwell, W. C. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.10.028 · Cited by 10
Martin, M. B., López, J. A., Corbacho-Alonso, N., Martínez, P. J., Rodríguez‐Sánchez, E., Mouriño-Álvarez, L., Sastre-Oliva, T., Martín-Rojas, T., Rincón, R., Calvo, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23037-7 · Cited by 10
Achi, H. E., Awwad, J. T., Daya, S. A., Halabi, S., Damianos, S., & Mahfouz, R. A. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4237-1 · Cited by 10
Recent AHA/ACC guidelines on cholesterol management expands the role of the clinical laboratory
Cao, J., & Devaraj, S. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.04.002 · Cited by 10
Self-citationHlaing, T., & Park, A. J. (2013) · Medicine · doi:10.1016/j.mpmed.2013.07.004 · Cited by 10
Chou, Y., Kuan, J.-C., Bai, C., Yang, T., Chou, W.-Y., Hsieh, P.-C., You, S., Hwang, L., Chen, C.-H., Wei, C., et al. (2014) · Endocrine · doi:10.1007/s12020-014-0447-z · Cited by 10
Metadata
- Authors
- Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R.
- Affiliations
- Maine Standards Company, Windham, ME
- Mayo Clinic (US)
- National Institutes of Health (US)
- National Institutes of Health, Bethesda, MD
- University of California Davis Medical Center (US)
- Marshfield Clinic (US)
- Berkeley HeartLab Inc, Alameda, CA
- Corresponding author
- Contois, John H
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-01
- Volume
- 55
- Issue
- 3
- Pages
- 407-419
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2107424758
- Cited by
- 326
- References
- 97
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 7 · 2023: 16 · 2022: 12 · 2021: 24 · 2020: 25 · 2019: 16 · 2018: 22 · 2017: 17 · 2016: 14 · 2015: 16 · 2014: 28 · 2013: 25 · 2012: 24
- FWCI
- 29.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein B, LDL particle number, LDL cholesterol, cardiovascular risk, lipid profile, Canadian guidelines, cardiovascular risk assessment
- MeSH terms
- Apolipoproteins B, Cardiovascular Diseases, Humans, Risk Factors, Clinical Chemistry Tests
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
